FY2024 EPS Estimates for Cencora, Inc. (NYSE:COR) Lifted by Analyst

Cencora, Inc. (NYSE:COR) – Stock analysts at Zacks Research increased their FY2024 earnings per share (EPS) estimates for Cencora in a note issued to investors on Wednesday, May 22nd. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $13.41 per share for the year, up from their prior forecast of $13.27. The consensus estimate for Cencora’s current full-year earnings is $13.45 per share. Zacks Research also issued estimates for Cencora’s Q1 2025 earnings at $3.17 EPS, Q2 2025 earnings at $3.92 EPS, Q3 2025 earnings at $3.58 EPS, FY2025 earnings at $14.58 EPS, Q1 2026 earnings at $3.39 EPS, Q2 2026 earnings at $4.38 EPS and FY2026 earnings at $15.80 EPS.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. The business had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. Cencora’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 earnings per share.

Other research analysts have also recently issued research reports about the company. Robert W. Baird lifted their target price on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Leerink Partnrs reiterated an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. Mizuho lifted their target price on Cencora from $192.00 to $224.00 and gave the company a “neutral” rating in a research report on Monday, February 5th. SVB Leerink started coverage on Cencora in a research report on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price on the stock. Finally, Citigroup lifted their target price on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $233.90.

Cencora Stock Up 1.4 %

COR stock opened at $219.82 on Thursday. The company has a market cap of $43.84 billion, a PE ratio of 24.05, a price-to-earnings-growth ratio of 1.51 and a beta of 0.47. The business has a 50-day simple moving average of $234.60 and a 200 day simple moving average of $222.17. Cencora has a 52 week low of $163.37 and a 52 week high of $246.75. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently added to or reduced their stakes in COR. Vanguard Group Inc. acquired a new position in shares of Cencora during the fourth quarter worth approximately $4,212,508,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Cencora during the first quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. acquired a new position in shares of Cencora during the first quarter worth approximately $1,199,695,000. Capital Research Global Investors acquired a new position in shares of Cencora during the first quarter worth approximately $650,424,000. Finally, Bessemer Group Inc. acquired a new position in shares of Cencora during the first quarter worth approximately $556,245,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cencora

In related news, EVP Elizabeth S. Campbell sold 6,977 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $238.12, for a total value of $1,661,363.24. Following the sale, the executive vice president now directly owns 8,246 shares in the company, valued at $1,963,537.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth S. Campbell sold 6,977 shares of the business’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $238.12, for a total value of $1,661,363.24. Following the completion of the transaction, the executive vice president now directly owns 8,246 shares in the company, valued at $1,963,537.52. The disclosure for this sale can be found here. Insiders have sold 75,295 shares of company stock worth $17,747,944 over the last ninety days. Insiders own 15.80% of the company’s stock.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 24th. Investors of record on Friday, May 10th will be issued a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Thursday, May 9th. Cencora’s payout ratio is presently 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.